Vera Therapeutics Inc - Class A — Quarterly Cash Flow (NASDAQ:VERA) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Total assets 655.68 M610.17 M578.53 M517.5 M734.73 M Total liabilities 78.53 M75.17 M110.25 M118.62 M130.21 M Total equity 577.15 M535 M468.28 M398.88 M604.52 M Total liabilities & shareholders' equities 655.68 M610.17 M578.53 M517.5 M734.73 M Total debt 54.64 M54.47 M77.55 M77.22 M77.31 M Net debt -586.21 M-535.37 M-479.27 M-420.17 M-637.28 M

뉴스

베라 테라퓨틱스, Wolfe Research, 투자의견 상향 조정

Wolfe Research upgrades Vera Therapeutics stock rating on valuation

베라 테라퓨틱스, BofA 증권 ’매수’ 등급 재확인

Vera Therapeutics stock rating reaffirmed at Buy by BofA Securities

Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

베라 테라퓨틱스, 이사회에 크리스토퍼 하이트 선임

Vera Therapeutics adds Christopher Hite to board of directors

3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026 - TipRanks.com

Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

VeraDermics is said to draw IPO anchor order from Eli Lilly - Bloomberg

베라 테라퓨틱스, Matt Skelton을 최고 상업 책임자로 승진 임명

Vera Therapeutics promotes Matt Skelton to chief commercial officer